Navigation Links
Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
Date:1/31/2013

SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital.  The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses.  Proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), the advancement of the Company's diagnostic platforms, and for general working capital. 

"With our recently reported positive efficacy data on MANF, and our newly acquired diagnostic platforms, this additional funding positions Amarantus to advance these assets for the potential treatment and diagnosis of Parkinson's disease and other apoptosis-related disorders," said Gerald E. Commissiong , President and CEO of Amarantus.  "This also provides us the opportunity to explore additional indications where our product candidates may be beneficial." 

In November 2012, Amarantus issued a Convertible Promissory Note to Dominion Capital, LLC in the principal amount of $600,000. On January 28, 2013, the note was amended to increase the principal amount of the note to $2,000,000.  The Note bears interest at the rate of ten percent (10%) per annum, is convertible into common stock at $0.10 per share, and is pre-payable at the company's option at any time. The financing commitments will be realized by Amarantus under the note in six separate tranches of $200,000 to $250,000, subject to certain milestone achievements. Dominion has agreed t
'/>"/>

SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinsons Disease
3. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
4. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
5. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Jan. 18 ,Exelixis, Inc. (Nasdaq: EXEL ) ... exercise its option to license XL784 for further,development ... meet its primary endpoint in a phase 2 ... in one subgroup were encouraging,Exelixis believes that the ...
... Specialty Pharmacy, one,of the largest privately owned national ... an agreement with Genzyme Corporation to,administer their 2008 ... the world,s largest biotechnology companies dedicated to products,and ... transplant, and oncology., Diplomat will be the ...
Cached Medicine Technology:GSK Does Not Option XL784 for Further Development 2GSK Does Not Option XL784 for Further Development 3Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program 2
(Date:12/26/2014)... 2014 The Biofeedback Federation of Europe ... 2015 in Rome, Italy and is hosted by the ... on a wide variety of topics such as ... performance training in athletes. The scientific program will feature ... Biofeedback monitoring allows clients to see what is going ...
(Date:12/26/2014)... Seattle, WA (PRWEB) December 26, 2014 ... to deal with personal injury claim issues and phone ... their recently released an article featuring their free ... The exceptionally helpful eBook on pedestrian and bicycle auto ... injury attorney is fully capable of professionally handling their ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3
... Pa., Sept. 29 Herley Industries,Inc. (Nasdaq: ... England division in,Woburn, Massachusetts, has a contract totaling ... NY, for the manufacture of,complex switch filter assemblies ... ("ESM") system., The MH-60R Multi-Mission Helicopter (MMH) ...
... some cases, unproven ,therapies, can be dangerous, experts say ... often turn to the Internet as a source of ... hopes are betrayed by purveyors of so-called cancer "cures" ... month, five companies were charged with making false and ...
... Mass., Sept. 29 LaVoie Group, a full-service,provider ... strategy to life science clients, today announced that ... record by cancer therapeutics,company, Neotropix(R), Inc., Donna ... commented, "We are,delighted to represent Neotropix during an ...
... of its truck accident practice area that will provide victims of ... to help them overcome the severity of the incident. The truck ... to the most recent jury verdicts. , ... Denver, ...
... PureWellness to bring Wellness Program to hundreds of locations. , ... ... a leading provider of online wellness solutions, announced it has signed ... food and nutrition services to hospitals and senior living communities across ...
... 29 SAFC Pharma(TM), a focus,area within SAFC(R), ... SIAL ),today announced details of a new suite ... that will produce high-potency active pharmaceutical,ingredient (HPAPI) conjugates ... will enable the conjugation of HPAPIs to a ...
Cached Medicine News:Health News:Herley New England Receives Additional $1.3 Million Contract Award from Lockheed Martin for the Multi-Mission Helicopter 2Health News:Scams and Shams That Prey on Cancer Patients 2Health News:Scams and Shams That Prey on Cancer Patients 3Health News:LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster 2Health News:LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents 2Health News:LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents 3Health News:Nation's Leading Food Services Provider Chooses PureWellness to Drive Corporate Wellness Program 2Health News:SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis 2Health News:SAFC Pharma Commissions HPAPI Conjugates Facility at St. Louis 3
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: